Ascelia Pharma Q1'25: FDA submission ahead - ABG

Orviglance FDA submission during the summer
Good cost control
Conf call at 10:00 CEST


Recent relevant events

In mid'March '25, Ascelia communicated a positive outcome of the pre-NDA meeting with the FDA. In mid'April, Ascelia finished the warrants TO 1 capital raise, raising gross proceeds of SEK 43m. On 7 May, Ascelia held its AGM in Malmö, adopting all resolutions on the agenda. All board members including the chairman of the board were re-elected. Earlier this week, Ascelia's CEO Magnus Corfitzen held a presentation at the ABG Investor days and Ascelia clinical collaborators presented SPARKLE data at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ascelia-pharma/Equity-research/2025/5/ascelia-pharma---q125-fda-submission-ahead/